期刊
JOURNAL OF ENDOCRINOLOGY
卷 211, 期 1, 页码 99-106出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/JOE-11-0094
关键词
-
资金
- Medical Research Council
- AstraZeneca
Proglucagon is cleaved to glucagon by prohormone convertase 2 (PC2) in pancreatic a-cells, but is cleaved to glucagon-like peptide-1 (GLP-1) by PC1 in intestinal L-cells. The aim of this study was to identify mechanisms which switch processing of proglucagon to generate GLP-1 in the pancreas, given that GLP-1 can increase insulin secretion and beta-cell mass. The alpha-cell line, alpha TC1-6, expressed PC1 at low levels and GLP-1 was detected in cells and in culture media. GLP-1 was also found in isolated human islets and in rat islets cultured for 7 days. High glucose concentrations increased Pc1 gene expression and PC1 protein in rat islets. High glucose (25 mM) also increased GLP-1 but decreased glucagon secretion from alpha TC1-6 cells suggesting a switch in processing to favour GLP-1. Three G protein-coupled receptors, GPR120, TGR5 and GPR119, implicated in the release of GLP-1 from L-cells are expressed in alpha TC1-6 cells. Incubation of these cells with an agonist of TGR5 increased PC1 promoter activity and GLP-1 secretion suggesting that this is a mechanism for switching processing to GLP-1 in the pancreas. Treatment of isolated rat islets with streptozotocin caused beta-cell toxicity as evidenced by decreased glucose-stimulated insulin secretion. This increased GLP-1 but not glucagon in the islets. In summary, proglucagon can be processed to GLP-1 in pancreatic cells. This process is upregulated by elevated glucose, activation of TGR5 and beta-cell destruction. Understanding this phenomenon may lead to advances in therapies to protect beta-cell mass, and thereby slow progression from insulin resistance to type 2 diabetes. Journal of Endocrinology (2011) 211, 99-106
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据